scPharmaceuticals Q4 2024 Earnings Report
Key Takeaways
scPharmaceuticals reported strong growth in Q4 2024 with FUROSCIX revenue doubling year-over-year. Despite higher revenues, the company faced increased operating expenses leading to a net loss. Key milestones included FDA approval for an expanded FUROSCIX indication and continued expansion efforts in Integrated Delivery Networks.
FUROSCIX revenue reached $12,150,000 in Q4 2024, up 99% year-over-year.
Net loss widened to $18,845,000 compared to $13,812,000 in Q4 2023.
Cost of product revenues increased to $3,965,000 in Q4 2024.
Cash and cash equivalents stood at $75,655,000 as of December 31, 2024.
scPharmaceuticals
scPharmaceuticals
scPharmaceuticals Revenue by Segment
Forward Guidance
scPharmaceuticals anticipates continued growth fueled by expanded indications, Medicare Part D redesign, and commercial efforts. The upcoming launch of FUROSCIX for chronic kidney disease and advancement of the SCP-111 autoinjector are key focus areas for 2025.
Positive Outlook
- FDA approval of FUROSCIX for chronic kidney disease treatment.
- Anticipated launch of the new CKD indication in April 2025.
- Continued strong growth in integrated delivery networks.
- Significant tailwinds from expanded field sales force.
- Full-year impact expected from Medicare Part D redesign.
Challenges Ahead
- Continued net losses and high operating expenses.
- Dependence on the commercial success of FUROSCIX.
- Risks related to manufacturing and product delivery.
- Potential financial constraints and need for future funding.
- Uncertainties due to global economic factors impacting operations.